Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-27.89 Insider Own0.30% Shs Outstand329.06M Perf Week0.77%
Market Cap61.33B Forward P/E10.99 EPS next Y16.96 Insider Trans0.00% Shs Float327.35M Perf Month4.38%
Income-9268.00M PEG- EPS next Q4.55 Inst Own92.10% Short Float3.26% Perf Quarter14.78%
Sales15.82B P/S3.88 EPS this Y24.90% Inst Trans1.92% Short Ratio4.53 Perf Half Y47.20%
Book/sh178.28 P/B1.05 EPS next Y0.15% ROA-9.50% Target Price187.53 Perf Year19.84%
Cash/sh13.85 P/C13.46 EPS next 5Y3.40% ROE-15.10% 52W Range114.27 - 186.90 Perf YTD39.44%
Dividend2.96 P/FCF10.66 EPS past 5Y-36.00% ROI-4.80% 52W High-0.28% Beta1.64
Dividend %1.59% Quick Ratio0.90 Sales past 5Y43.40% Gross Margin85.00% 52W Low63.10% ATR1.55
Employees16900 Current Ratio1.00 Sales Q/Q3.60% Oper. Margin-60.30% RSI (14)75.36 Volatility0.71% 0.85%
OptionableYes Debt/Eq0.39 EPS Q/Q- Profit Margin-58.50% Rel Volume0.62 Prev Close186.08
ShortableYes LT Debt/Eq0.32 EarningsNov 05 BMO Payout- Avg Volume2.36M Price186.37
Recom2.70 SMA201.38% SMA505.54% SMA20019.28% Volume1,457,477 Change0.16%
Nov-19-19Downgrade UBS Buy → Neutral $189 → $203
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jul-18-19Downgrade SVB Leerink Outperform → Mkt Perform
Jul-16-19Downgrade Bernstein Outperform → Mkt Perform
Jun-11-19Initiated Barclays Underweight $133
May-28-19Initiated Goldman Neutral
Apr-15-19Initiated Jefferies Hold
Mar-20-19Initiated SunTrust Buy $178
Jan-31-19Downgrade Credit Suisse Outperform → Neutral
Jan-30-19Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-30-19Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-09-18Resumed Guggenheim Buy
Apr-24-18Resumed Citigroup Buy $200
Apr-23-18Resumed Evercore ISI Outperform
Apr-17-18Initiated Stifel Hold $192
Feb-23-18Initiated SunTrust Buy $200
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Dec-05-19 04:54PM  John Paulson's Top 5 Buys in the 3rd Quarter GuruFocus.com
11:31AM  Allergan (AGN) Up 4.5% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 05:26PM  Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine PR Newswire
10:10AM  AstraZeneca Sells Schizophrenia Drug Rights in US and Canada Zacks
10:00AM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
05:00AM  Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018 American City Business Journals
Nov-29-19 02:00PM  Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019 PR Newswire
12:36PM  Private Capital Exits Allergan, Universal Health Services GuruFocus.com
08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-28-19 07:00AM  The 3 Worst-Performing Health Care Stocks of 2019 So Far Barrons.com
Nov-27-19 11:10PM  Here is the 23rd Most Popular Stock Among 752 Hedge Funds Insider Monkey
07:06PM  3 Stocks for Value Investors to Buy as Market Reaches New High Zacks
Nov-26-19 06:06PM  National Consumer Rights Law Firm FeganScott Files Second, Expanded Class-Action Lawsuit Against Allergan TEST Business Wire Releases
06:06PM  National Consumer Rights Law Firm FeganScott Files Second, Expanded Class-Action Lawsuit Against Allergan Business Wire
Nov-20-19 09:30AM  Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
Nov-19-19 11:39AM  Mason Hawkins' Southeastern Buys 1, Sells 2 in 3rd Quarter GuruFocus.com
11:22AM  Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association PR Newswire
09:31AM  Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks
Nov-18-19 05:19PM  Daniel Loeb's Top 5 Buys in the 3rd Quarter GuruFocus.com
02:25PM  Mason Hawkins Sells Alphabet, General Electric GuruFocus.com
07:30AM  Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day PR Newswire
Nov-17-19 06:41AM  Hedge Funds Open Kimono: Here Are Their Top 5 Large-Cap Stock Picks Insider Monkey
Nov-14-19 06:24PM  Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter GuruFocus.com
10:05AM  Allergan, Exicure Strike Collaboration Agreement For Hair Loss Disorder Drugs Benzinga
08:28AM  Exicures shares up on Allergan partnership MarketWatch
06:00AM  Beware of Runs on Bond Funds Barrons.com
05:01AM  AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know Barrons.com
Nov-13-19 01:00PM  Biohaven Readies for David Versus Goliath Battle with Allergan Bloomberg
12:03PM  AbbVie Takes on Debt to Buy Allergan GuruFocus.com
10:46AM  AbbVies $30 Billion Bond Sale Was Wall Streets Biggest This Year Barrons.com
10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
09:35AM  The Zacks Analyst Blog Highlights: Booking, Allergan, Honda Motor, Infosys and Activision Blizzard Zacks
Nov-12-19 05:12PM  AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition Bloomberg
03:24PM  How KKR Could Pull Off a Walgreens Takeover Barrons.com
02:08PM  Top Stock Reports for Booking Holdings, Allergan & Honda Motor Co. Zacks
06:46AM  AbbVie sells $30bn of bonds to finance Allergan takeover Financial Times
05:00AM  AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report TheStreet.com
Nov-11-19 05:13PM  Allergan CEO on Innovation and Blockbuster Biopharmaceuticals Bloomberg
10:32AM  The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J Zacks
07:30AM  Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections PR Newswire
Nov-08-19 05:48PM  Patients Sue Breast-Implant Manufacturer Allergan, Says Consumer-Rights Law Firm FeganScott Business Wire
09:59AM  Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase Zacks
09:38AM  With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback InvestorPlace
09:26AM  Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products Zacks
Nov-07-19 10:51AM  Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed Zacks
10:18AM  AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's new sr. notes; stable outlook Moody's
Nov-05-19 06:16PM  Vanguard Health Care Fund Sells Out of Allergan GuruFocus.com
03:57PM  2 Stocks to Watch Tuesday GuruFocus.com
11:02AM  Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View Zacks
10:48AM  Allergan's Q3 Sales Get A Facelift From Botox; AbbVie Deal On Track Benzinga
08:58AM  Euphoric investors trigger alarm bells over stock market rally MarketWatch
08:15AM  Allergan (AGN) Q3 Earnings Meet Estimates Zacks
07:38AM  Allergan's stock gains after adjusted profit, revenue beat expectations MarketWatch
07:00AM  Allergan Reports Third Quarter 2019 Financial Results PR Newswire
04:40AM  [video]Allergan Tops Q3 Earnings, Bumps 2019 Sales Guidance Amid AbbVie Takeover TheStreet.com
Nov-04-19 01:08PM  Allergan Q3 Earnings Preview Benzinga
12:28PM  Marine algae keys Chinese claim to Alzheimers breakthrough MarketWatch
12:27PM  Day Ahead: Top 3 Things to Watch Investing.com
11:23AM  Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More Zacks
10:00AM  Should You Buy Allergan (AGN) Ahead of Earnings? Zacks
09:15AM  Allergan (AGN) Hits 52-Week High, Can the Run Continue? Zacks
Nov-02-19 08:30AM  How the frugality of U.S. corporations saved third-quarter results from the abyss MarketWatch
Nov-01-19 04:21PM  AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms Investor's Business Daily
02:47PM  AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View Zacks
11:07AM  WIll Allergan (AGN) Beat Estimates This Earnings Season? Zacks
11:05AM  Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings? Zacks
10:52AM  Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks
10:42AM  Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings? Zacks
10:10AM  AbbVie says multiple parties vying for assets related to Allergan deal approval Reuters
09:04AM  AbbVie Delivers on Earnings and Raises Forecast Barrons.com
08:46AM  UPDATE 2-AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales Reuters
08:05AM  Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates Benzinga
07:49AM  AbbVie lifts 2019 profit forecast as Humira helps beat revenue estimates Reuters
05:35AM  [video]AbbVie Posts Stronger-Than-Expected Earnings, Lifts Forecast TheStreet.com
Oct-30-19 11:46AM  Mylan (MYL) to Report Q3 Earnings: What's in the Offing? Zacks
Oct-29-19 10:33AM  Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 02:26PM  China could quickly become the worlds largest antidepressant market, but hurdles remain MarketWatch
10:24AM  RPT-UPDATE 1-Allergan settles Alzheimer's therapy lawsuit for $750 million Reuters
09:13AM  Allergan settles Alzheimer's therapy lawsuit for $750 million Reuters
09:00AM  FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs PR Newswire
08:42AM  Allergan to book $750 million pre-tax charge in Q3 after settlement of Navenda class-action suit MarketWatch
08:31AM  Forest Resolves Antitrust Class Action Litigation with Direct Purchasers of Namenda PR Newswire
Oct-25-19 11:10AM  What's in the Cards for AbbVie (ABBV) This Earnings Season? Zacks
10:32AM  5 Undervalued Stocks to Buy InvestorPlace
10:28AM  Allergan Finance, LLC -- Moody's assigns Baa2 to AbbVie's exchange note offering Moody's
10:10AM  Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report? Zacks
08:11AM  AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes PR Newswire
07:00AM  Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share PR Newswire
Oct-24-19 07:30AM  FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy PR Newswire
Oct-23-19 03:26PM  16 Stocks With The Highest Long-Term Sales Growth Rate Benzinga
07:30AM  Allergan Presents Data From Eleven Abstracts At The 2019 American Society for Dermatologic Surgery (ASDS) in Chicago PR Newswire
Oct-21-19 12:24PM  J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos Zacks
08:08AM  UPDATE 9-Drug firms avert landmark opioid trial as talks on $48-bln settlement set to resume Reuters
Oct-18-19 09:11PM  UPDATE 6-Opioid settlement talks fail, landmark trial expected Monday Reuters
10:57AM  Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow Zacks
07:00AM  Judge's unorthodox approach has huge opioid settlement within reach Reuters
Oct-17-19 07:00AM  Allergan to Report Third Quarter 2019 Financial Results PR Newswire
Oct-16-19 12:16PM  Editas Inks Deal for Gene Editing Neurological Disease Drugs Zacks
12:02PM  'High-level dope dealers': Democratic candidates sound off on big pharma Yahoo Finance
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has a collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and gene therapy research collaboration with The National Institute for Bioprocessing Research and Training. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LChairman, President and CEOMar 07Buy143.671,760252,858170,666Mar 07 03:19 PM